{
    "title": "Roche lymphoma drug drives high remission rate, longer survival-study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5164631/Roche-lymphoma-drug-drives-high-remission-rate-longer-survival-study.html",
    "date": "2017-12-10",
    "keywords": [
        "response",
        "therapy",
        "cancer",
        "polatuzumab",
        "roche",
        "drug",
        "rate",
        "combination",
        "bill",
        "berkrot",
        "treatment",
        "trial",
        "meeting",
        "bcell",
        "dlbcl",
        "addition",
        "percent",
        "remission",
        "blood",
        "midstage",
        "sunday",
        "diffuse",
        "lymphoma",
        "disease",
        "rituxan",
        "tevas",
        "treanda",
        "reduction",
        "risk",
        "death",
        "society",
        "hematology",
        "atlanta",
        "survival",
        "population",
        "benefit",
        "magnitude",
        "horning",
        "officer",
        "head",
        "product",
        "development",
        "competition",
        "blockbuster",
        "oncology",
        "avastin",
        "herceptin",
        "type",
        "medicine",
        "effect",
        "protein",
        "majority",
        "lymphomas",
        "designation",
        "food",
        "administration",
        "priority",
        "advance",
        "duration",
        "phase",
        "ii",
        "study",
        "safety",
        "company",
        "growing",
        "form",
        "zieminski"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}